Jefferies Financial Group Begins Coverage on Avalo Therapeutics (NASDAQ:AVTX)

Jefferies Financial Group assumed coverage on shares of Avalo Therapeutics (NASDAQ:AVTX) in a research note released on Tuesday, Marketbeat.com reports. The firm issued a buy rating and a $23.00 target price on the stock.

Other analysts have also issued reports about the stock. BTIG Research initiated coverage on shares of Avalo Therapeutics in a research report on Thursday, December 19th. They set a “buy” rating and a $40.00 price target for the company. Piper Sandler assumed coverage on shares of Avalo Therapeutics in a research report on Friday, February 28th. They set an “overweight” rating and a $48.00 target price for the company. Stifel Nicolaus initiated coverage on shares of Avalo Therapeutics in a report on Tuesday. They issued a “buy” rating and a $36.00 price target on the stock. HC Wainwright reaffirmed a “neutral” rating on shares of Avalo Therapeutics in a research report on Thursday, March 20th. Finally, Wedbush reissued an “outperform” rating and issued a $18.00 price objective on shares of Avalo Therapeutics in a research report on Thursday, March 20th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat.com, Avalo Therapeutics has an average rating of “Moderate Buy” and an average target price of $33.00.

Avalo Therapeutics Stock Up 11.9 %

Shares of NASDAQ AVTX opened at $8.54 on Tuesday. Avalo Therapeutics has a twelve month low of $4.60 and a twelve month high of $34.46. The business has a fifty day simple moving average of $7.51 and a two-hundred day simple moving average of $9.14.

Hedge Funds Weigh In On Avalo Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC lifted its holdings in shares of Avalo Therapeutics by 998.4% in the 4th quarter. Tower Research Capital LLC TRC now owns 4,130 shares of the company’s stock valued at $31,000 after buying an additional 3,754 shares during the period. Marshall Wace LLP purchased a new stake in shares of Avalo Therapeutics during the fourth quarter worth about $114,000. Walleye Capital LLC acquired a new stake in Avalo Therapeutics in the 4th quarter worth about $145,000. Northern Trust Corp purchased a new stake in Avalo Therapeutics during the 4th quarter worth approximately $168,000. Finally, Bank of Montreal Can acquired a new position in shares of Avalo Therapeutics during the fourth quarter valued at approximately $446,000. Hedge funds and other institutional investors own 87.06% of the company’s stock.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.